MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.65
+0.37
+5.89%
After Hours: 6.68 +0.03 +0.45% 19:55 06/11 EDT
OPEN
6.42
PREV CLOSE
6.28
HIGH
6.84
LOW
6.23
VOLUME
2.26M
TURNOVER
--
52 WEEK HIGH
20.00
52 WEEK LOW
0.6906
MARKET CAP
185.60M
P/E (TTM)
-16.6960
1D
5D
1M
3M
1Y
5Y
UiPath, Campbell among premarket losers' pack
Ondas Holdings ONDS -17% after securing $44.8M capital via equity raise.CEL-SCI CVM -12% after securing $31.7M capital raise.UiPath PATH -10% on Q1 earnings release.United Natural Foods UNFI -9% on FQ3 earnings release.Eastman Kodak (KODK) -10%.Campbell So...
Seekingalpha · 4d ago
Second Sight Medical files for $250 million mixed securities shelf offering
Photo by smirart/iStock via Getty Images Second Sight Medical Products (EYES) has filed for a prospectus to issue $250M worth of securities in a mixed shelf offering. The company shares have lost
Seekingalpha · 4d ago
Second Sight Medical Products Files for $250 Million Mixed-Securities Shelf Offering
MT Newswires · 4d ago
BRIEF-Second Sight Medical Products Inc Files For Mixed Shelf Of Upto $250 Mln
reuters.com · 5d ago
Second Sight Medical Products Files For Mixed Shelf Of Up To $250M
-SEC Filing
SEC Filing · 5d ago
Global Bioelectric Medicine Market Share Estimated to Reach USD 36 Billion by 2026: Facts & Factors
Facts and Factors have published a new research report titled "Bioelectric Medicine Market By Product (Implantable Cardioverter Defibrillators, Cardiac Pacemakers, Cochlear Implants, Deep Brain Stimulators, Transcutaneous Electrical Nerve Stimulators, V...
GlobeNewswire · 6d ago
64 Biggest Movers From Friday
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous glucose monitoring dev...
Benzinga · 6d ago
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 06/04 16:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYES. Analyze the recent business situations of Second Sight Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYES stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 63
Institutional Holdings: 4.34M
% Owned: 15.56%
Shares Outstanding: 27.91M
TypeInstitutionsShares
Increased
7
627.87K
New
14
2.16M
Decreased
3
43.78K
Sold Out
6
78.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.06%
Key Executives
Chairman/Director
Gregg Williams
Chief Executive Officer
Scott Dunbar
Vice President - Operations
Ted Randolph
Vice President
Edward Randolph
Other
Stephen Okland
Director
Alexandra Larson
Director
Jonathan McGuire
Independent Director
Dean Baker
Independent Director
Aaron Mendelsohn
Independent Director
Matthew Pfeffer
No Data
  • All
  • Financials
  • Insiders
More
About EYES
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYES stock methods without spending real money on the virtual paper trading platform.